Efficiency Without Integrity is Just Well-Organized Failure. It's Time to Revisit the FDA "Fast-Track" Mind Set and Replace it with "Never Forget"
Cutting corners in the name of translational science incurs errors with penalties in the form of serious adverse effects and poor health, both medical and economic.
Efficiency: A Word We Need to Take Back
There are moments in the evolution of language when a word becomes unrecognizable—when its usage drifts so far from its origin that what once conveyed wisdom now conceals harm. “Efficiency” is one of those words. It used to mean something noble. It meant clarity of process, elegance in design, rigor in the elimination of waste—not of oversight, not of safeguards, not of memory.
In engineering, efficiency is the difference between a finely tuned machine and one that hemorrhages energy. In ecology, it reflects the flow of energy across systems that balance growth and limitation. In science, it should mean thoughtful iteration: knowledge refined, mistakes caught early, systems structured to self-correct. But in our time, the word has been co-opted—not by scientists, but by strategists, bureaucrats, and profit engineers who have come to wield it like a cudgel.
Now, “efficiency” means something else entirely. It means skipping steps. It means defunding oversight bodies. It means outsourcing expertise to consultants who know the contract better than they know the science. It means collapsing trial phases meant to serve as temporal firewalls between human experimentation and mass deployment. It means normalizing the abnormal—and dressing speed in the costume of success.
If you want to understand the collapse of institutional trust over the last five years, start here. Not with conspiracy, but with confluence: a convergence of language, narrative engineering, and structural incentives that redefined caution as cowardice and vigilance as inefficiency. A subtle sabotage of science occurred, not in the lab, but in the boardroom—and it was sanctioned at the highest levels of regulatory authority.
We were told that speed was essential. That lives depended on rapid development. That innovation demanded flexibility. And to some extent, that was true. But what was quietly discarded along the way—what was dismissed as friction—was the entire infrastructure designed to prevent large-scale harm. Safety monitoring became optional. Redundancy was labeled waste. Dissent became misinformation. And time itself was framed as the enemy of progress.
But time is not the enemy. Time is the medium in which truth emerges. Adverse reactions don’t always appear within a two-week window. Patterns take months—sometimes years—to cohere. Safety, if it means anything at all, must mean having the patience to let complexity reveal itself before declaring certainty.
We must take this word—efficiency—back. Reclaim it not for speed’s sake, but for the sake of truth. True efficiency requires a system that functions not only when conditions are favorable, but when the unexpected occurs. It demands mechanisms for learning, layers of feedback, structural humility. It recognizes that the greatest cost is not in delay, but in failure.
The cost of redefining efficiency as speed is no longer theoretical. It is written into the injury reports, the uninvestigated deaths, the unexplained illnesses. It is etched into the faces of those who trusted institutions that no longer trusted themselves to slow down.
This article is not just a critique. It is an autopsy. It is a map. And it is a call—to those who still believe that science is more than consensus, more than acceleration, more than PR. It is a call to return to rigor. To structure. To truth. And yes, to real efficiency—the kind that protects lives, not just rollouts.
Theater of Oversight: FDA’s Contractor Shuffle
When an institution begins to act in contradiction to its stated purpose, the public may sense something is off—but often struggles to name it. That’s because the language of betrayal rarely announces itself. It is procedural. Administrative. Dry. But every now and then, the veil lifts. And what it reveals is something worse than negligence—it reveals performance.
That’s what happened in 2024, when the U.S. Food and Drug Administration executed one of the most quietly devastating acts of regulatory self-evisceration in its modern history. Hundreds of experienced inspectors and support personnel were dismissed from the FDA’s Office of Regulatory Affairs. Their crime? Being part of the very machinery designed to ensure that what enters our bodies has been checked—by hand, by eye, by expertise—for contamination, compliance, and fraud. The rationale? Efficiency.
And yet, in an almost laughable twist of institutional schizophrenia, many of those roles were then quietly filled by private contractors—at higher cost. The work did not vanish. It was simply outsourced, depersonalized, and decontextualized.
Let us not miss what this means.
It means that those with tacit knowledge of the regulatory landscape—those who knew how to read inspection logs like forensic accountants, who could smell the difference between a mistake and a pattern—were cast out. Their work was handed to temps and vendors who know little beyond the script in front of them. This is not modernization. This is memory loss at scale. It is the replacement of institutional intelligence with procedural checkboxing. And it is profoundly dangerous.
Since those terminations, food and drug safety inspections have declined by over 36% compared to pre-pandemic levels. What makes this more than a budget story—what makes this a scandal—is that the decline was framed as progress. Risk was sold as innovation. This was not a temporary lapse in coverage; it was a deliberate downgrade in regulatory complexity. And it happened under the banner of "efficiency."
This is what happens when language is manipulated to serve ends it was never designed to defend. You can’t make a system more efficient by cutting out the parts that catch failure. That’s not optimization. That’s deregulation by stealth. It’s science stripped of its safety net. It’s public trust thrown overboard so that the ship can move faster—never mind that it’s heading for the reef.
We are told to trust the FDA. But when that agency begins to act like a contracting agency rather than a scientific one, trust becomes an act of faith, not of reason. And the American people were not called to faith; they were promised facts.
So here is a fact: when you remove the people whose job it is to say “no,” the only ones left are those paid to say “yes.”
That is not oversight. It’s theater.
And behind the curtain, nothing is being watched.
Fast Track Before—and After—COVID
To understand how the American drug approval process became a race instead of a review, you have to go back before the pandemic—before Operation Warp Speed, before the phrase “emergency use” was whispered into every newsroom.
You have to go back to the era when expedited review was still a privilege—a rare exception carved out for patients with terminal illness, rare diseases, and no alternatives. That was the original mandate of Fast Track: a compassionate, narrowly tailored allowance for cases where delay posed a death sentence, and where the risks of inaction outweighed the potential harms of speed.
Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) at the FDA, was a strong advocate of this mechanism long before SARS-CoV-2 ever entered the human lexicon. To be fair, his motivations were not entirely misplaced: in the context of ultra-rare diseases or genetic disorders, a drawn-out trial may indeed doom those who have no time. But what began as an accommodation—an ethically nuanced, medically sensitive exception—was transformed into a doctrine.
And COVID-19 was the crucible.
With Operation Warp Speed and the FDA’s broad invocation of Emergency Use Authorization (EUA), the ideals of slow, layered clinical progression gave way to the fetishization of acceleration. The pandemic granted social license to regulators to treat the normal rules as barriers—and to treat caution as cruelty. In the public eye, speed became synonymous with saving lives. But in reality, what accelerated was not just innovation, but risk exposure, systemic blind spots, and statistical fragility.
That’s how EUA, Fast Track, Accelerated Approval, and Breakthrough Therapy Designation became stackable badges of speed, layered like armor to fend off scrutiny. One by one, traditional milestones of drug evaluation—extended animal studies, long-term follow-up, diverse subgroup analysis—were recast as bureaucratic dead weight. What mattered now was time to market. What mattered was perception of progress.
And what was lost in this shift? The space in which adverse events can be meaningfully seen. The time required for signals to cohere. The confidence earned—not demanded—in the safety of a product before its release into the general population.
The consequences are not academic. The failure to maintain robust trial buffers led to a cascade of serious adverse events that were only detected after mass administration. Myocarditis in young men. Neurological effects in women. Menstrual cycle disruptions. Clotting disorders. Autoimmune activations. These were not discovered in the lab. They were discovered in the population, in real time, as humans became the final data set.
Fast Track is now embedded in the operating system of public health—no longer an exception, but the default mode. And that’s not just a bureaucratic error. It’s an epistemological crisis.
Because if your entire system of evidence-generation is predicated on learning after rollout, then what you have built is not a safety system—it’s a live experiment with no control arm, no pause button, and no transparency.
The question isn’t whether we needed vaccines quickly. The question is whether we were honest about what was sacrificed in the process.
And whether, now that the urgency has faded, we will have the courage to reverse course—or whether we will institutionalize the very thing that should have remained extraordinary.
Fauci & Collins: The Collapse of Caution
In clinical science, time is not the enemy—it is the crucible in which safety is tested, failure is caught, and signal becomes meaning. In the development of medical interventions, particularly vaccines, the integrity of temporal structure in trial design is not optional. It is foundational.
That’s what makes the decision to collapse Phase II and Phase III clinical trials during the COVID-19 vaccine rollout such a watershed moment in regulatory history—a moment that Anthony Fauci, then Director of NIAID, and Francis Collins, then Director of the NIH, both publicly endorsed and operationalized under the imprimatur of urgency.
The Structure They Collapsed
Let us be clear about what each trial phase is meant to accomplish:
Phase I evaluates basic safety, tolerability, and dosing in a small group of healthy volunteers (typically fewer than 100).
Phase II expands to hundreds of participants, exploring a range of dosing regimens, refining safety profiles, and testing biological plausibility and early signs of efficacy in the target population.
Phase III, conducted on thousands to tens of thousands, is a powered efficacy trial with statistical robustness. It assesses protection from disease and actively monitors for adverse events across age, sex, race, comorbidities, medications, and genetic variation.
The temporal separation of these phases serves not only as a technical milestone but as a safeguard against pushing unknown risks into the public sphere. Each phase is a conditional gateway—a “checkpoint” system that slows down harm before it scales.
Fauci and Collins, in collaboration with Operation Warp Speed and the ACTIV public-private partnership, publicly supported and helped execute adaptive, “seamless” trial models that effectively merged Phase II and III—running them concurrently with overlapping enrollment and early unblinding protocols to hasten data collection.
“We’ve never tried anything like this before. Normally this would take years... We’re going to do it in months.”
—Francis Collins, NIH Director’s Blog, 2020
In the same week, in early 2021, both Fauci and Collins told media outlets that they thought - their opinion, not fact - they believed that combining Phases II and III was essential to get the vaccine out as soon as possible. But collapsing trial phases isn’t just speeding things up. It compresses the resolution of the clinical lens. It makes some safety signals mathematically undetectable until the product has already reached millions. The fusion of these phases robs the study of the opportunity to validate the initial adverse events.
It also means less time to observe delayed effects, less statistical power to detect rare events, and insufficient data granularity to stratify by subpopulations at risk—for example, adolescents, the elderly, autoimmune patients, or women of reproductive age.
The Cost of That Collapse
The consequences were immediate and predictable—so predictable, in fact, that many scientistics and some clinicians warned of them in real time, only to be dismissed or de-platformed. Key safety signals emerged after mass rollout rather than during controlled observation:
Myocarditis and pericarditis, especially in males under 30 following mRNA vaccination, were not detected during trials, which enrolled too few young men to observe statistically significant events.
Menstrual cycle irregularities were reported globally by women—but dismissed as anecdotal because menstrual effects were never formally studied or captured in pre-authorization safety questionnaires.
Neurological events, including paresthesias, tremors, Guillain-Barré syndrome, and in rare cases, fatal encephalitis, were detected via post-market surveillance, not proactively through trial design.
Autoimmune flares, thrombocytopenia, and clotting anomalies (including VITT) were not accounted for because these conditions were exclusion criteria in trials—not test cases.
These outcomes would not have been invisible if time had been respected as a scientific variable.
Instead, they were deferred to post-market surveillance systems—systems that rely on voluntary reporting, underreporting-adjusted estimates, and signal detection algorithms never intended to replace prospective clinical data.
The fact is, we may never know the full scope of long-term vaccine effects in some populations, because those populations were either excluded or insufficiently powered in stand-alone Phase II and III studies.
Precision Delayed Is Precision Denied
To make matters worse, while the vaccine trial design was collapsed, public health policy expanded to include everyone—from healthy toddlers to the elderly, regardless of prior infection, immune status, or comorbid risk. No risk stratification. No evidence-based tailoring.
The result was not only a scientific failure but an ethical one.
And now, in April 2025, we see the clean-up crew arrive. The CDC’s Advisory Committee on Immunization Practices (ACIP) is finally deliberating over whether to recommend COVID-19 vaccines based on risk factors like age, prior immunity, and comorbid burden—a conversation that should have shaped their earliest policies.
This isn’t progress. It’s retroactive justification for harm. It's a bureaucratic mop-up.
And it all began when the highest echelons of American science abandoned sequence for speed—replacing the ancient discipline of trial timing with the shallow dogma of “warp.”
The warped process they adopted was one of the things that fractured the very foundation of modern safety science.
This was not an administrative detail. It was not a minor procedural adaptation. It was a deliberate dismantling of the chronological scaffolding upon which modern safety science rests. It was cutting corners of the rubber life raft. Fauci and Collins both denied that combining Phase II and III trials was cutting corners.
Phase II trials exist to assess dosing, early safety (generate a list of putative safety signals), and the biological plausibility of efficacy. Phase III trials are designed to test that efficacy in larger populations and to monitor adverse events across subgroups in hopes of finding those adverse events again (i.e., replication). Each phase is a membrane of protection—a pressure-tested firewall between uncertainty and exposure.
By collapsing those phases, we did not merely “speed up” science. We removed its parachute.
This decision—championed by leadership at the NIH, and unopposed by regulators who should have known better—meant that serious adverse events which normally would have been caught early were instead detected in the post-market population. Not just in case reports, but in hospitals. On autopsy tables. In VAERS entries written by grieving parents. In the silence of disrupted menstrual cycles and the sudden absence of neurological clarity.
This is not how public health is supposed to work. Not by a long shot.
We were told that “extraordinary times require extraordinary measures.” But what was extraordinary about this measure was how permanently it altered the expectations of evidence. It taught institutions that process was negotiable—and it taught the public that dissent about that process was synonymous with danger.
The long-term implications of this trial collapse are still unwinding. ACIP—CDC’s own vaccine advisory body—is only now, in April 2025, considering risk-based vaccine recommendations for COVID-19 products. Think about that. We are four years into mass administration of a product given to hundreds of millions, and only now are we publicly discussing which populations benefit and which may be harmed. Only now are we retrofitting a framework for precision risk assessment that should have been embedded from day one.
This is the residue of speed. Not just in design, but in decision-making. Not just in trials, but in the theology of urgency that overtook the entire regulatory ethos from 2020 onward.
You cannot accelerate beyond complexity and pretend you’ve solved it.
You can only ignore it long enough to create a new kind of crisis—one that looks nothing like the virus we feared, but everything like the institutional collapse we were too afraid to name.
Source: https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/05-Panagiotakopoulos-COVID-508.pdf
Tale of Two Standards: Pharma vs. Prevention
In theory, science is impartial. It does not recognize profit margins, lobbying power, or branding. It concerns itself only with truth—its detection, its validation, its reproducibility. But in the real world of regulatory medicine, the scientific method must kneel before the economic model, and evidence is not judged on its strength alone, but on who pays to collect it.
Nowhere is this disparity more visible than in the regulatory divide between high-cost pharmaceutical products and low-cost, repurposed, or preventative therapies.
Tier 1: Expensive, Patented, High-Incentive Interventions
For products developed by major pharmaceutical corporations—with patent exclusivity, billion-dollar projections, and favorable media campaigns—flexibility is the norm. The following allowances are routinely made:
Fast Track and Accelerated Approval, often granted on the basis of surrogate endpoints rather than hard clinical outcomes.
Use of small, underpowered trials justified by “unmet medical need.”
Rolling submissions that allow partial data delivery during review.
Deferred post-market obligations often fulfilled years after widespread use begins—if ever.
Expedited timelines for breakthrough or emergency designations, even in non-emergency settings.
In these cases, the phrase “extraordinary circumstances” is stretched to cover the ordinary incentives of profit and market timing.
For example, the FDA’s Accelerated Approval program—originally created to expedite treatments for HIV and rare cancers—has now been used for over 150 products, many of which cost patients and insurers hundreds of thousands of dollars per course, and lack confirmatory trials for years.
Reference: https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approvals
Tier 2: Low-Cost, Repurposed, or Preventative Therapies
Contrast that with the fate of interventions that are:
Off-patent
Widely available
Cheap
Or rooted in lifestyle, nutritional, or ecological models of health
In these cases, the regulatory burden becomes Sisyphean. Agencies and journals routinely reject such therapies for “lack of rigorous evidence,” even when:
Plausibility is high
Safety profiles are well known
Initial observational data are promising
Examples are plentiful:
Vitamin D, despite decades of immunological research and strong inverse correlations with respiratory viral outcomes, has been treated as a fringe curiosity—its trials underfunded and their statistical power criticized.
Fluvoxamine, an SSRI with anti-inflammatory properties, showed early promise in reducing COVID-19 hospitalization in the TOGETHER trial. The trial was well-designed, yet its impact on policy was muted.
Melatonin, a known immunomodulator with anti-oxidative and circadian regulatory properties, has shown potential in reducing viral replication and inflammation, yet is ignored in favor of less established pharmaceutical options.
Dr. Brownstein’s Protocol Case Series
Meanwhile, no equivalent pressure is placed on vaccine manufacturers to demonstrate long-term efficacy, reduction in all-cause mortality, or even confirmed reductions in transmission—goals that are implied in public messaging but absent in the regulatory criteria.
The Regulatory Paradox
This is the paradox: The more expensive and complex a product is, the less rigorous its evidentiary burden seems to be. It’s similar to the Great Sliding Scale of Evidence for Causation: If it’s a vaccine, you need to move mountains. If it’s a virus, someone only has to whisper that they image that a virus COULD be the cause. The cheaper and more universal a therapy is, the more impossible it becomes to move through the gate. That’s why I wrote and published #CuresVsProfits in 2015… I wanted to study how effective and safe medicines came to market in spite of profit pressure.
Why do cheap solutions get passed over? Because there is no sponsor to shepherd it through the $500 million process of randomized, multicenter, double-blind, placebo-controlled trials across diverse populations. No shareholder to justify the expense. No lobbyist to leverage “public-private partnerships.” No room in the drug pricing schema to justify a return on investment.
The science hasn’t failed. The structure has.
We are not living in a world where all interventions must meet the same standard. We are living in a world where standards are market-graded. Evidence is filtered through profit potential, and what emerges is not a hierarchy of truth—but a hierarchy of funded narratives.
The casualties are not only therapies lost to bureaucracy, but the trust of a population who sees—clearly—that some science gets a red carpet, and some gets a brick wall.
Survivorship Bias: The Safety Illusion
There is a kind of data error so insidious that even seasoned analysts fail to detect it at first glance. It doesn’t come from measurement error or statistical noise. It comes from what is missing. Not what is present in the dataset, but what is absent—and why. In the case of vaccine safety and pharmaceutical efficacy, this phenomenon has a name: survivorship bias.
It is the bias born of the invisible: those who do not continue, who drop out, who suffer an early harm and are quietly removed from the cohort. These are the people who disappear from long-term follow-up datasets—not because they died, necessarily, but because their outcomes were unfavorable early enough to disqualify their continued participation. They stop responding. They are excluded for protocol noncompliance. Or they are silently, bureaucratically filtered out by design.
This bias is not theoretical. It is baked into the structure of nearly every post-marketing study, especially those that rely on passive surveillance, observational registries, or electronic health records. And it is dramatically amplified in clinical trials that merge phases, abbreviate follow-up windows, or launch with such urgency that attrition tracking becomes an afterthought rather than a requirement.
Consider what happens when a serious adverse event occurs in a vaccine recipient shortly after dose administration. If that participant drops out, and the event is not causally attributed by the sponsor or investigator, that case may not appear in safety summaries at all. It may be logged in VAERS. It may be treated as a one-off. It may even be blamed on comorbidity or stress. But what it does not become is a durable part of the official efficacy calculation.
As the study continues, those who remain are, by definition, those who tolerated the product—those whose physiologies were either not vulnerable, or not pushed to their threshold. These participants accumulate time, good outcomes, and reinforcing data. The curve flattens. The illusion of safety sharpens.
This is how drugs and biologics appear increasingly safe the longer a study runs, not because they are safe, but because those who suffered early harm are statistically scrubbed from view.
In a vaccine trial, where a single dose is given but adverse events may take weeks or months to develop—or appear only upon subsequent exposures—this bias becomes fatal to truth. It gives policymakers false reassurance. It empowers manufacturers to cite “real-world data” that omits the people whose real-world experience was deemed uncountable. And it leaves regulators with a skewed mirror, reflecting only what has survived, not what was harmed.
Survivorship bias is the ultimate sleight-of-hand in systems already optimized for speed. And it is nearly impossible to detect from the outside unless you are looking for it—unless you are asking: Who didn’t make it to Day 60? Who dropped out before antibody titers were measured? Whose adverse event led to exclusion, not elevation, in the data?
This is not paranoia. It is well-documented in methodological literature, particularly in post-market pharmacovigilance and vaccine pharmacoeconomics. One 2022 review in Therapeutic Advances in Drug Safety emphasized that failure to account for early dropout or pre-enrollment adverse reactions can “severely underestimate harm and overestimate benefit, particularly in risk-stratified groups.”
SOURCE: https://pubmed.ncbi.nlm.nih.gov/35008121/
And yet, when critics raise these concerns—when they dare to suggest that dropout matters, or that VAERS data can signal real harm—they are labeled alarmists, their analyses relegated to appendices or stripped of context in rebuttals signed by stakeholders.
Survivorship bias is not merely a statistical quirk. It is a moral blind spot in modern medicine. It rewards indifference and penalizes caution. It ensures that the data we use to justify interventions reflects only those who were least affected—while those most affected are made silent, again and again.
If science is to mean anything, it must be capable of counting the harmed. And if efficiency is to mean anything, it must include mechanisms that prevent harm from being algorithmically erased.
Institutional Memory Loss and the Mirage of Machine Insight
There is a quiet death that institutions die long before collapse. It is not the loss of funding or the failure of leadership. It is the loss of memory—the evaporation of history not from documents, but from practice. It happens when the people who remember where the failures occurred, how they emerged, and why they were missed are pushed out in the name of renewal. Or more often: in the name of efficiency.
This is not a romantic argument for seniority or tenure. It is a hard, structural truth. Every regulator, every inspector, every medical reviewer who stays long enough in their role develops an internal map: where the paperwork tends to lie, where the hidden thresholds are missed, how a false pass emerges from language rather than from data.
When those people are dismissed—when seasoned field agents are replaced with consultants, contractors, and artificial intelligence systems that optimize for rules rather than wisdom—the memory of error disappears. And with it goes the capacity to anticipate the next iteration of that error, cloaked in new protocols, embedded in slightly better marketing, but functionally identical to what failed before.
We saw this clearly in 2024, when the FDA offloaded core inspection duties to outside firms, claiming modernization. What they did not say is that those contractors could not possibly know which facilities had a history of delayed remediation. Which firms had played the line on labeling language in 2011. Which overseas labs had a history of good audits paired with suspiciously stable assay data.
That knowledge was not written down. It was carried in people. And once they were gone, the algorithm could only guess.
Now enter the age of predictive analytics. Across the FDA, CDC, and global health regulators, we are witnessing the rise of machine learning systems designed to anticipate where failure will occur. On paper, it sounds like progress. These models parse adverse event reports, identify textual clusters in inspection findings, and flag manufacturing lots that deviate from quality norms.
But these tools are only as good as the data they are fed. And they are being trained on datasets already riddled with survivorship bias, underreporting, and the systemic blind spots created by regulatory phase collapse. When your inputs are filtered through years of structural forgetting, your outputs will reflect that amnesia. Worse: they will look objective.
AI does not “know” that a facility with perfect records might have submitted ghostwritten documentation. It doesn’t “remember” when a particular batch of excipient caused subtle toxicity in early trials. It cannot read between lines that were never printed.
Human beings, particularly those with years of domain-specific experience, can.
The danger is not that AI will make mistakes. It’s that we will stop looking for them, trusting the appearance of insight without testing its memory.
Real regulatory safety systems are built not only on detection, but on intuition born of pattern exposure. A good inspector doesn’t just follow a checklist; they feel when a process seems rehearsed. A strong clinical reviewer doesn’t just read a trial report; they sense when a table has been overfitted to the narrative.
You cannot code for that.
We are told that AI will catch more signals, more quickly, with less cost. But efficiency gained at the cost of memory is not efficiency—it is brittle acceleration. It is optimization of a system that no longer remembers what it was designed to prevent.
If we replace memory with models, and judgment with heuristics, we will learn nothing from the last five years. We will only become better at repeating them—faster, cheaper, and with less resistance.
This is not a call to abandon technology. It is a call to integrate it with reverence for human insight. It is a warning that the most dangerous system is not one that fails, but one that appears to function while its foundational wisdom has already been deleted.
The future of safety cannot be predicted unless the past is preserved.
Narrative Control: The Efficient Silencing of Signal
Public health, when functioning correctly, is a collective epistemology. It is not simply the act of issuing guidance. It is the process by which evidence is gathered, weighed, contested, refined, and finally translated into action. This process only works when dissent is not only tolerated—but encouraged. Science, if it is real, is adversarial. It depends on challenge, contradiction, and friction.
But in the wake of COVID-19, friction became the enemy. Dissent became the virus.
What emerged instead was a vision of public health as narrative management. Under the guise of “efficiency,” agencies no longer viewed transparency and skepticism as scientific virtues. They viewed them as threats to uptake.
And so, for the first time in modern history, agencies tasked with protecting the public began coordinating with technology platforms to actively suppress legitimate scientific discourse.
This was not speculative. It is documented. In the so-called Twitter Files, released in late 2022 and confirmed by internal communications, we saw evidence that the CDC, NIH, and the White House requested the censorship of posts from scientists and physicians raising concerns about the emerging safety signals, or even questioning the universal applicability of mass vaccination strategies.
This was not fringe content. These were credentialed individuals citing peer-reviewed literature. But they were flagged—first manually, then algorithmically—as obstacles to “public confidence.” Their content was downranked. In some cases, their accounts were locked.
SOURCE: https://x.com/davidzweig/status/1607378386338340867
The rationale was efficiency: we need more uptake, less confusion. We need harmony in the message. We need speed—not just in product development, but in compliance.
This may have seemed pragmatic to those inside the machine. But from the outside, from the view of the thinking public, it looked like something else: a coordinated effort to prevent scientific self-correction.
And that is exactly what it was.
This is what happens when “efficiency” is extended from the laboratory to the communications department. Suddenly, a scientist asking for longer-term follow-up becomes a disruptor. A physician noting a pattern in adverse events becomes a “vaccine hesitant influencer.” A mother sharing her child’s injury becomes a “misinformation vector.”
The goal, it seems, was not to prevent harm. It was to prevent discussion of harm.
And that makes sense if your model of efficiency is throughput alone—number of shots, number of compliant citizens, number of headlines praising the response.
But if your model of efficiency includes the integrity of the scientific record, then this strategy is not just a failure—it is a betrayal.
Because signals are fragile. They arrive first as whispers. One VAERS entry. A letter to the editor. A small cluster noticed by a local nurse. If your system is designed to muffle those whispers instead of amplify them, you will miss the avalanche that follows.
And that is what we did.
The efficient suppression of scientific dissent is not a side note. It is not a public relations detail. It is the hallmark of a broken epistemic system—one that fears perception more than it fears error.
You cannot prevent harm by hiding it.
And you cannot serve the public if you are busy managing its opinion instead of protecting its health.
No Accountability: Compensation Without Consequence
If you wanted to design a system optimized for speed but immune to feedback—one that could ignore emerging harms without consequence—you would begin by removing any legal or financial risk from the parties who produce those harms. That’s exactly what happened under the Public Readiness and Emergency Preparedness (PREP) Act, which granted sweeping liability protection to manufacturers of COVID-19 countermeasures, including vaccines, regardless of outcomes.
In effect, the PREP Act created a regulatory black hole, into which accountability disappeared. This wasn’t theoretical—it was structural. If a product failed, if a child suffered an injury, if a healthy adult developed a disabling adverse reaction, there would be no civil litigation, no discovery process, no trial, and no jury. No opportunity to examine emails, to question safety protocols, to compel transparency. The courtroom was replaced by a form. The legal system was replaced by bureaucratic silence.
In place of accountability, the government offered the Countermeasures Injury Compensation Program (CICP)—an obscure administrative mechanism operated by the Department of Health and Human Services. Unlike the more familiar National Vaccine Injury Compensation Program (NVICP), which allows for limited legal representation and public hearings, the CICP is non-transparent, non-adversarial, and fundamentally inaccessible.
It does not allow discovery. It does not permit appeals. It operates entirely at the discretion of the Secretary of HHS. As of 2025, over 97% of all CICP claims related to COVID-19 vaccines have been denied, often on the basis of “insufficient evidence” or the refusal to recognize causality absent randomized control-level proof—proof that was never collected, because the trial timelines were collapsed, and the post-market surveillance systems were built to miss it.
CICP Page: https://www.hrsa.gov/cicp
The result is a legal and ethical chasm. Those harmed by the products of government partnerships have no recourse. Manufacturers are shielded. Regulators deny knowledge. Lawmakers defer to bureaucrats. And the injured are left not only with their injuries—but with the message that their experience does not exist within the architecture of recognition.
This is not just bad policy. It is a complete inversion of ethical medicine. The foundational covenant of public health—the balance of risk and benefit—was replaced by a one-sided wager: benefits accrue to the population, but risks are borne entirely by individuals.
This is how you end up with safety systems that don’t detect harm, and compensation systems that don’t acknowledge it. It’s not a glitch. It’s the design.
The PREP Act was passed in the spirit of emergency. But like many emergency powers, it has calcified into precedent. Now, there is no incentive for manufacturers to build safer products, because there is no cost for building unsafe ones. No litigation means no pressure to improve. No discovery means no lessons learned. No transparency means no informed public.
This, too, was sold to us as “efficiency.” But what it efficiently removed was the final check on institutional failure: the law.
You cannot have safety without accountability. You cannot have informed consent without informed systems. And you cannot claim to protect the public while silencing the harmed.
The real emergency is that we still call this justice.
The Mirror in Finance: Deregulation as “Efficiency” by Another Name
When a structure begins to collapse, it rarely does so in isolation. Cracks appear in the language before they appear in the foundations. And when one domain—biomedical regulation—normalizes acceleration, deregulatory rhetoric, and the removal of public safeguards, it is only a matter of time before other domains follow suit.
That’s what we’re witnessing now in finance. And the parallels are as chilling as they are clarifying.
In early 2025, the U.K. Treasury launched a consultation proposing to raise the threshold for regulatory oversight of hedge funds and private equity firms from €100 million to £5 billion—a fiftyfold increase in the assets allowed to operate outside the purview of full accountability. The justification? To reduce “administrative burden.” To encourage “innovation.” To promote “agility” in the post-Brexit financial ecosystem.
Sound familiar?
These are the same words that accompanied the deregulation of vaccine safety protocols. The same words that preceded the gutting of food and drug inspection staff at the FDA. The same script, just read from a different podium.
Let’s be honest: what the Treasury is proposing is not simplification. It is strategic opacity. It is the invitation to allow vast sums of speculative capital to move through global markets without friction—without the institutional brakes that were installed after the 2008 financial crisis to prevent exactly this kind of overexposure.
And what’s most revealing is the language surrounding the proposal. Risk, we are told, is now a feature—not a flaw. Regulation, we’re assured, stifles growth. Transparency, we’re warned, is expensive. These are not policy arguments. They are ideological reframings, designed to pre-empt criticism and sanitize recklessness.
But the public has heard these arguments before.
We heard them when biologics were fast-tracked before long-term genotoxicity data were available. We heard them when surveillance of vaccine injuries was deferred to passive reporting systems designed to miss what mattered. We heard them when pharmaceutical executives appeared on news shows to explain that “we don’t have time to wait for tradition.”
What’s happening in the financial sector is not unrelated. It is parallel collapse. Different actors, same script: call it “efficiency,” sell it as progress, and when the damage arrives—externalize it.
This is how systems collapse in the modern age. Not through open rebellion, but through the bureaucratic laundering of responsibility. Institutions don’t announce that they’re offloading risk onto the public. They say they’re “empowering markets.” They don’t admit that they’re deleting safety nets. They say they’re “cutting red tape.” And when it all unravels? They call it unforeseeable.
But it was foreseeable. It still is.
Because the same doctrines that dismantled regulatory science in medicine are now dismantling financial stability and confidence in all science. And the same people—those most affected—will be the last to know, and the first to pay.
You can call it deregulation. You can call it reform. But it is neither. It is the abdication of foresight dressed as modernization.
And it will fail, as all such schemes do—not because it moves too slowly, but because it moves too fast to see the wreckage it leaves behind.
Bringing Epistemics to Regulatory Science
The failures of the past five years—real, measurable, global—did not arise because we lacked data. They arose because we did n ot know how to think about the data we had. They emerged not from the absence of science, but from the absence of a functioning epistemology within science.
We mistook models for proof. We replaced the friction of challenge with the smoothness of consensus. We called uncertainty “misinformation,” and we enforced stability where systems needed debate. In short, we had protocols—but not philosophy. We had regulatory machinery—but no epistemic backbone.
This is the crisis at the heart of regulatory science. It is not only a crisis of integrity or independence. It is a crisis of how we know what we claim to know.
We’ve built systems that are structurally blind to emergent harms. Not because they lack computing power, but because they were not designed to accommodate real-time challenge. They are optimized for approval, not discovery—for speed, not synthesis. And without an epistemic framework that privileges testability, falsifiability, reproducibility, and transparency, these systems devolve into theater.
If we want to repair public trust—and not merely repair the optics of public trust—we must bring epistemics back into regulatory science.
This means designing systems that do not just process evidence, but ask what kind of evidence is valid, and under what conditions it can be trusted. It means that risk isn’t just minimized through exclusion criteria and trial filtering—it is interrogated as a moral imperative. It means that dissenting interpretations aren’t silenced—they’re stress-tested and integrated.
To bring epistemics into regulation is to ask at every step:
What do we know?
How do we know it?
What are we assuming?
Who has the power to define certainty?
And what have we built to ensure we can detect when we’re wrong?
It means knowing the difference between statistical significance and real-world relevance. Between absence of evidence and evidence of absence. Between predictive modeling and empirical validation. Between regulatory approval and truth.
And it means rejecting the dogma that speed, scale, and simplification are neutral virtues. They are tools. And like all tools, they can build or destroy. Without epistemic accountability—without philosophical humility—those tools become blunt instruments. Worse, they become weapons wielded against the very people they are meant to protect.
Regulatory systems must be restructured around epistemic integrity. This includes:
Sequential, non-collapsed trial phases that reflect biological complexity.
Mandatory inclusion of long-term, adverse event-sensitive endpoints.
Transparency not just in data, but in assumptions, limitations, and uncertainties.
Independent review boards with no economic or political entanglements.
Open-source pharmacovigilance systems that allow real-time third-party analysis.
Protections for dissenting scientists—not punishments.
To rebuild science, we must stop treating knowledge as a product and start treating it as a process of discovery, debate, and provisional confidence.
Anything less is not science. It is simulation.
Anything less is not protection. It is policy theater.
And anything less will collapse again.
Collapse Wasn’t Inevitable. But Recovery Must Be Deliberate.
The failures we’ve traced in this essay—regulatory, ethical, epistemic—were not the result of bad luck. They were not unforeseeable. They were not, as we are so often told, the regrettable collateral damage of innovation. They were the predictable consequence of designing systems to perform rather than to perceive—systems that equated acceleration with intelligence, and public compliance with public good.
They were not inevitable. But now that we know them, what happens next is up to us.
We do not fix structural failure with better messaging. We do not repair scientific collapse with press releases or blue-ribbon panels. What we need is not more haste, but more structure. More rigor. More deliberate design.
To move forward, we must reconstitute the architecture of regulatory science around one principle: epistemic integrity. And that means more than being right. It means building systems that know how to know—that can detect their own blind spots, that welcome contradiction, that respect the biological, psychological, and social complexity of human experience.
So here, at the end of the long arc of institutional self-sabotage we’ve just walked through, we make the call—not for return, but for reinvention.
What must happen next:
We must abolish the fusion of trial phases for any public health intervention with population-wide implications. No more collapsing Phase II/III for convenience. Biological signal emergence is not a bureaucratic variable—it’s a temporal necessity.
We must rebuild a regulatory firewall between product manufacturers and safety assessors. Not one step further can be taken in trust until the FDA, CDC, and NIH disentangle themselves from the financial and reputational outcomes of the products they are supposed to evaluate.
We must require long-term safety endpoints for all vaccine products, not just acute reactogenicity. This includes neurological, autoimmune, reproductive, and all-cause mortality follow-up.
We must end the use of passive surveillance as a proxy for active pharmacovigilance. Signal detection must be real-time, automated, and audited by independent, third-party systems with public oversight.
We must remove liability shields like the PREP Act and replace them with systems that allow for public redress and scientific accountability. CICP must be replaced by a transparent, appealable, publicly overseen structure where causality determinations are not a political process, but a scientific one.
We must ban narrative control agreements between public health agencies and social media companies. No public agency may use its power to suppress lawful speech. Truth is forged in dialogue, not dictated by decree.
We must enshrine epistemic humility into law. Every public health recommendation must be accompanied by a statement of uncertainty, known limitations, and non-consensus views among independent experts. Science without uncertainty is no longer science—it is marketing.
These reforms are not radical. What is radical is pretending we can go on as if nothing has been learned.
And yet reforms at the institutional level will mean nothing if the public remains epistemically disempowered—conditioned to trust slogans rather than inquire, to accept consensus rather than investigate, to defer rather than engage.
That’s why the real project must begin with you.
If you want to reclaim your agency, if you want to be more than a compliant endpoint in someone else’s dataset, you must learn to think like a scientist—an independent scientist. That’s where real reform begins.
➤ Educate yourself through IPAK-EDU, the only educational platform designed to empower citizens as epistemic agents—people who know not just what to think, but how to know.
➤ Support IPAK, the Institute for Pure and Applied Knowledge, where independently structured, policy-defiant science is still happening—still asking the hard questions, still publishing the unpopular truths, and still building the foundation for the systems we will need tomorrow.
The cost of truth is resistance. The cost of resistance is isolation. But the cost of surrendering science to speed, silence, and spectacle is incalculable.
If you’ve made it this far in this essay, you already understand: you are not a bystander. You are a stakeholder. And the future of science will be shaped by what you now choose to support, to build, and to protect.
Not for optics. Not for narrative. But for knowledge that endures, because it was earned the hard way—and made safe for the people it was meant to serve.
You are not a bystander. You are a stakeholder. And the future of science will be shaped by what you now choose to support, to build, and to protect.
So read deeply. Question courageously. Learn deliberately. Fund fearlessly.
Begin at IPAK-EDU.org. Support the engine at IPAKnowledge.org.
Wow! Such an excellent comprehensive visit across a variety of landscapes that are interconnected and responsible for bringing us to this place.
Bravo! Let’s hope this goes viral.
This is a spectacular piece! It deserves widespread attention. Submit this article to that new journal "The Journal of Independent Medicine". I think it's one of the only journals that doesn't censor material like this.